Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.56 |
| ▸ | WNT3A | P56704 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875364 | 0.87 | CNR1 (0.58) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL12450809 | 0.85 | CNR1 (0.56) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL12450018 | 0.85 | CNR1 (0.56) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL6812882 | 0.85 | CNR1 (0.56) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL8728950 | 0.83 | CNR1 (0.63) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL30257325 | 0.83 | CNR1 (0.63) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL9040996 | 0.81 | CNR1 (0.62) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL8728849 | 0.80 | CNR1 (0.60) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL9144238 | 0.80 | CNR1 (0.60) | CNR1CTNNB1WNT3ASRD5A1SRD5A2 | |
| SCHEMBL2647988 | 0.80 | CTNNB1 (0.55) | CTNNB1WNT3APTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513395-B2 | Method for the synthesis of anthocyanins | BIOSYNTH AS (NO) | 2013-08-20 | — | — | US | disclosed |
| US-8513395-B2 | Method for the synthesis of anthocyanins | BIOSYNTH AS (NO) | 2013-08-20 | — | — | US | disclosed |
| EP-1891086-B1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | BIOSYNTH AS (NO) | 2011-08-24 | — | — | EP | disclosed |
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | BIOSYNTH AS (NO) | 2009-04-30 | — | — | US | disclosed |
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | BIOSYNTH AS (NO) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | POR, SPR, G6PD | CNR1 3919/4885CTNNB1 3942/4885WNT3A 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.